The short answer
Have passionflower reviewed before combining it with alprazolam. The evidence does not establish a universal avoidance or separation rule for this exact pair.
What this answer covers
Oral Passiflora incarnata aerial-part preparations; other species and mixtures are distinct.
- Supplement or preparation
- Passiflora incarnata
- Medication ingredient
- alprazolam
What official guidance says
The passionflower monograph notes possible driving impairment, but lists no reported interactions. This supports attention to alertness without proving that alprazolam co-use must always be avoided.
The human studies did not test this pair
Two short perioperative studies found no significant added sedation or psychomotor impairment with their passionflower products. Alprazolam combination safety was not assessed.
Check the specific product
List species, plant part, extract and any other sleep or anxiety ingredients. There is no validated time gap that answers the missing co-use evidence.
Protect your alertness
Alprazolam can impair coordination and alertness. Avoid driving when affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about all other sedating medicines and alcohol.
Evidence and practical considerations
Side effects & toxicity
Product review is appropriate but broad avoid/separate claim remains insufficient; traditional sedative use is not direct interaction proof.
- Exact scope
- Oral Passiflora incarnata aerial-part preparations; other species and mixtures are distinct. with Exact oral alprazolam; no blanket benzodiazepine metabolic or route transfer.
- Medication form and route
- oral; other cannabis routes only if explicitly discussed
- Timing or duration
- Exact duration and dose depend on source; single-dose and chronic use are distinguished.
What remains uncertain
- No exact alprazolam co-use trial identified; monograph lists no reported interactions and short perioperative trials found no added sedation.
Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alprazolam.
CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. Metabolism involves CYP3A; inhibitors and inducers may alter exposure. Not the same metabolic pathway profile as oxazepam or temazepam.
How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.
Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.
Source 2: official guidance
ema.europa.eu · Source check Sep 10, 2026
Population: People considering the specified supplement.
Traditional sleep-aid use; may impair driving. Section 4.5 lists no reported interactions.
How this applies: Preparation-specific context; not a directly measured alprazolam interaction.
Traditional-use monograph, not a alprazolam trial. No reported interaction is not proof of safety.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults undergoing ambulatory surgery.
Anxiety decreased, but sedation and psychomotor recovery were similar between groups.
How this applies: Preparation-specific context; not a directly measured alprazolam interaction.
Short perioperative exposure to one product, no alprazolam; does not establish chronic combination safety.
Source 4: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults aged 25-55 undergoing spinal anesthesia.
No significant group differences in sedation, psychomotor function, hemodynamics or side effects.
How this applies: Preparation-specific context; not a directly measured alprazolam interaction.
Selected perioperative population, no alprazolam; not proof that all preparations lack impairment.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries. | |
| Research summary published |
Article revision: 2d1a343568ee4acd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.